Allelic variants of cytochrome P450: CYP1A1, CYP1A2, CYP19 (Aromatase) and II-phase enzyme Sulfotransferase (SULT1A1) genes are associated with a high risk of hormone-dependent cancers. We estimated a frequency of these allelic variants in the female Caucasian population of the Novosibirsk region of Russia and their association with the elevated risk of ovarian and endometrial cancer. A DNA bank of gynecologic oncology patients, patients with benign gynecologic diseases and healthy women was created, and the following single nucleotide polymorphisms (SNPs) were examined: CYP1A1 M1 polymorphism, that is, T264-C transition in the 3 0 -noncoding region; CYP1A2*1F polymorphism, that is, C734-A transversion in CYP1A2 gene; C-T transition (Arg264Cys) in exon 7 of CYP19; SULT1A1*2 polymorphism, that is, G638-A transition (Arg213His) in SULT1A1 gene. A positive correlation of C allele of CYP1A2*1F and G allele of SULT1A1*2 with hormone-dependent cancers in women was found. Thus, these genes are appropriate candidates for studying the contribution of genetic factors to endocrine disorder and environmentally determined diseases susceptibility. In contrast, no association of CYP19 and CYP1A1 polymorphisms with increased cancer risk was revealed.
Introduction
Genetic polymorphisms in drug-metabolizing enzymes contribute to susceptibility to a number of diseases. Identification of certain allelic variants of drugmetabolizing enzymes as genetic susceptibility markers can provide an important tool in early diagnosis and prevention. Recently, a worldwide increase in the frequency of female hormone-dependent cancers has been observed, primarily due to endometrial, ovarian and breast cancers. Endometrial cancer (EC) is the most common gynecological cancer. Statistics indicate the case rate of EC in Russia in 1970 was 6.4 per 100 000 women. In 2001, this number has increased to 19.49, with an increase of 8-10% annually. 1 In the Novosibirsk region of Russia, the annual rate of increase is 9.4%, and for the last 20 years the case rate of EC has doubled, with the rate among women of reproductive age increasing from 7 to 15 per 100 000 women. 2 Ovarian cancer (OC) is another type of hormonedependent cancer. In Russia, the case rate of this disease has increased for the last 20 years. The mortality rate is high; the main reason is an advanced stage of the disease at initial diagnosis.
Identified risk factors for hormone-dependent cancers include endocrine disorders, environmental factors and genetic predisposition. The genetic nature of hormonedependent cancer is supported by the fact that in the Novosibirsk region there is an increase in the number of first-degree relatives diagnosed with cancer (e.g., mother with EC, daughter with breast cancer, son with colon cancer) as well as an increase of the number of patients previously living in areas with radiation (Semipalatinsk, Northern Kazakhstan, Altai region) in excess of background. 2 The risk of hormone-dependent cancer is directly or indirectly related to reproductive hormones, in particular, estrogens. 3 The main reason for this is thought to be estrogen stimulation of cell proliferation in the target organs. The whole process of estrogen metabolism is quite complex, but it can be divided in three main stages: synthesis, metabolism and detoxification. The key enzyme in the complex chain of biochemical reactions during the synthesis of estrogens from androgens is the cytochrome P450, subfamily 19 (CYP19 or aromatase). 4 Estrogens are metabolized by several enzymes, including cytochrome P450 1A1 and 1A2 (CYP1A1 and CYP1A2), through hydroxylation resulting in reactive metabolites. [5] [6] [7] [8] Further degradation of these metabolites via detoxification pathways, involves participation of sulfotransferase 1A1 (SULT1A1). 9 This enzyme catalyzes the sulfate conjugation of estrogens metabolites, forming hydrophilic sulfates of estrogens which are excreted in the urine. Endocrine system disturbances may occur through changes in the activities of enzymes involved. The CYP1A1, CYP1A2, CYP19 as well as SULT1A1 phenotypes vary between human individuals, suggesting the possibility of genetic component in the activities of these enzymes. This relationship has been confirmed by several studies. [10] [11] [12] [13] [14] [15] The purpose of our study was to estimate a frequency of allelic variants of CYP19, CYP1A1, CYP1A2 and SULT1A1 and their association with the elevated risk of hormonedependent cancer in the female population of the Novosibirsk region of Russia.
Results
For the detection of germline mutations in genes encoding four selected estrogen-metabolizing enzymes, the PCR-RFLP method was used. The genotype and allele distributions for CYP1A1, CYP1A2, CYP19 and SULT1A1 polymorphisms for both patients and controls are given in Table 1 . There was not a significant difference in both genotype and allele distributions for CYP1A1 and CYP19 polymorphisms in patients with benign or malignant tumors. In contrast, significant differences in the genotype and allele distributions for CYP1A2 polymorphism between patients with malignant tumors and controls were found. Comparison of allele frequencies revealed a deficiency of A allele of CYP1A2*1F in cancer patients compared to controls (P ¼ 0.0003) and these results were still statistically significant after Bonferroni correction for multiple testing. We found no statistical differences (P ¼ 0.097) between patients with benign tumors and the control group. CYP1A2 AA homozygotes exhibited a reduction of malignant tumor risk (P ¼ 0.0003) and these results were also significant after Bonferroni correction. CYP1A2 CA heterozygotes and CC homozygotes exhibited an increase of tumor risk (P ¼ 0.0027 and P ¼ 0.0139, respectively), but these results did not remain statistically significant after Bonferroni correction. Significant differences were found in the genotype and allele distribution for SULT1A1 polymorphism between patients with malignant tumors and controls as well as between patients with benign tumors and controls. Comparison of allele frequencies revealed a deficiency of allele A of SULT1A1*2 in patients with benign tumors (P ¼ 0.0014) and with malignant tumors (P ¼ 0.0192) compared to controls. However, when a Bonferroni correction was applied the differences between patents with malignant tumors and controls were not statistically significant. SULT1A1 AA homozygotes exhibited a reduction of malignant tumor risk (P ¼ 0.0068) and benign tumor risk (P ¼ 0.000004) while AG heterozygotes exhibited an increase of benign tumor risk (P ¼ 0.0061). However, after correction for multiple comparisons only results of reduction of benign tumor risk for SULT1A1 AA homozygotes remained statistically significant.
Discussion
Female hormone-dependent tumors, such as endometrial and ovarian carcinomas, are among the most common malignancies afflicting women from both developing and developed countries. 3, 16 A preponderance of evidence indicates that these cancers are multifactorial diseases, with genetic susceptibility, environment, nutrition and lifestyle risk factors playing important etiologic roles. Currently, a prevailing concept in the mechanisms of female hormonedependent cancer appearance is the impairment of estrogen metabolism in general, and 17-beta estradiol (E2), in particular. This impairment results in the increased concentration of hormones circulating in blood, or a local increase of their content in target tissues. 17 The genetic nature of such disorders may also contribute to disease development. For example, genetic variations of estradiol metabolism have been described as significant contributors to disease susceptibility, with variations depending on ethnic background. In the field of obstetrics and gynecology, the genetic contribution of polymorphic markers to a series of disorders has been characterized. 18 Identification of at-risk groups for developing hormone-dependent tumors is one of the most promising approaches to ultimately preventing these diseases.
In the current work, we report the genetic polymorphism of selected estrogen-metabolizing enzymes. A significant difference in genotypes and allele distributions was obtained for two genes studied. The cytochrome P450 1A2 allele variants can be considered as a risk factor for many human cancers. This is a major phase I enzyme, and accounts for about 15% of total liver P450 content. 19 This enzyme is most active in catalyzing 2-hydroxylations of 40-50% of circulating estrogens. 7, 8 Increased formation of 2-hydroxylated estrogens would be consistent with a reduced risk for breast cancer under a 'receptor-mediated' hypothesis, because 2-hydroxyestrogens can bind only weakly to the estrogen receptor. 20 In our study, the frequency of C allele of CYP1A2*1F was higher in women with hormone-dependent cancer, in agreement with a previous study. 21 These results suggest that women with C allele of CYP1A2*1F, which is associated with a decrease in CYP1A2 enzyme activity, have a higher risk of developing endometrial or OCs.
A major pathway for estrogen metabolism in humans is sulfate conjugation catalyzed by SULT enzymes, which enhance the solubility and renal excretion of steroids. Thus, steroid sulfonation contributes to the control of levels of biologically active hormone in target tissues. Inherited low Values in parentheses are Bonferroni corrected P-values (32 tests).
Estrogen-metabolizing gene polymorphisms
ON Mikhailova et al activity of SULT may increase the risk of breast cancer. 22 For the SULT1A1 a nucleotide substitution G638-A has been identified, resulting in an Arg213His substitution accompanied by a decrease in activity. 15 In contrast to expected results, patients with benign and malignant gynecological tumors in the Novosibirsk region had a higher frequency of G allele of SULT1A1*2 compared to healthy women. This may indicate that women with tumors have increased SULT1A1 activity compared to healthy women. This can be related to the dual functionality of the SULT family: inactivation of estrogens in addition to activation of procarcinogens. To date, little information is known about the balance between these functions and risk factors that these enzymes play. In our case, we can suggest a potential environmental component in hormone-dependent carcinogenesis, since SULT1A1 converts not only estrogens but also heterocyclic amines and aromatic amines into reactive metabolites. 23 It follows from this that the role of SULT1A1 in estrogen inactivation is not essential. A study of SULT1E1, the major estrogen-inactivating enzyme, would help clarify the role of sulfonation in hormonal carcinogenesis. The recently discovered polymorphism of this enzyme 24 is a subject of further investigation in our laboratory.
Our data did not indicate any significant differences in genotypes and allele frequencies both for CYP1A1 and CYP19 polymorphisms in patients compared to healthy controls. These results are in agreement with the recent publication, which showed only a weak association of MspI polymorphism in CYP1A1 gene with hormone-dependent cancer. 25 The absence of correlation for CYP19 polymorphism and cancer in our case is supported by other investigators. 26 This might be explained by the fact that contribution of genetic component in aromatase activity is not the only factor for cancer development. The concept of local estrogen biosynthesis due to increased aromatase activity is one of the leading factors for the development of estrogendepending tumors for today. 27 According to this concept the local synthesis of estrogens in single cells resulting in the variation of estrogen content and, as a consequence, enhancement of proliferation processes was accepted. 28, 29 In conclusion, the results of our study indicate that women with C allele of CYP1A2*1F or G allele of SULT1A1 in the Novosibirsk region of Russia have an increased risk of endometrial or OC.
Materials and methods
A DNA bank of cancer patients and healthy women of Novosibirsk region was created, utilizing two experimental groups -patients with different stages of endometrial or ovarian tumor malignancy (n ¼ 168, 19-55 years old) and patients with benign gynecological tumors (n ¼ 172, 19-55 years old) -and a group of healthy controls over the age of 55 with an uncomplicated obstetric and gynecological history (n ¼ 172). Clinical diagnosis was performed by board-certified gynecologic-oncologists from the Regional Clinical Oncological Hospital of Novosibirsk. Prior to study enrollment, the aims of the study were fully explained and informed consent was obtained from each patient. The study protocol was reviewed and approved by the appropriate Institutional Review Boards.
Genotyping of the studied population utilized the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Exfoliated buccal cell samples were collected from patients as a source of genomic DNA for genotyping assays. DNA was isolated from buccal epithelium using the MasterAmp Buccal Swab DNA Extraction Kit (BIOzym, Germany). Following precipitation, DNA samples were dissolved in 10 mM Tris/1 mM EDTA, pH 8.0 and stored at 41C.
Respective PCR reactions for each gene were performed in a total volume of 50 ml of buffer solution containing PCR buffer (10 mM Tris-HCl, pH 8.3; 1.5 mM MgCl 2 ; 50 mM KCl), 0.2 mM of each deoxynucleotide triphosphate; 20 pmol of each primer (in the primer pair), 100 ng of genomic DNA and 2 U of Taq DNA polymerase (purchased in Medigen, Novosibirsk, Russia). The PCR cycling conditions were as follows: denaturation at 951C for 3 min followed by 35 cycles of denaturation at 951C for 30 s, annealing at 621C for 30 s and extension at 721C for 1 min. A final extension step at 721C for 10 min was followed by cooling to 41C. The oligonucleotide primers for CYP1A1, CYP1A2, CYP19 and SULT1A1 were synthesized by Medigen company, Novosibirsk, Russia (http://www.medigen.ru) according to sequences chosen using the PCR primer design software GeneRunner (available at http://www.generunner.com) to ensure specific and efficient amplification of target sequences. The oligonucleotide primer sequences were:
SULT1A1 R, 5 0 -GCTGTGGTCCATGAACTCCT-3 0 .
We studied the following single nucleotide polymorphisms (SNPs): CYP1A1 M1 polymorphism, that is, T264-C in the 3 0 -noncoding region giving rise to an MspI restriction site; C734-A transversion in CYP1A2 gene abolishing an ApaI restriction site; C-T transition (Arg264Cys) in exon 7 of CYP19 gene which creates a recognition site for the SfaNI restriction enzyme; and a G638-A transition (Arg213His) in SULT1A1 gene that eliminates an HhaI restriction site. The amplified DNA fragments were digested with MspI (for CYP1A1), ApaI (for CYP1A2), SfaNI (for CYP19), HhaI (for SULT1A1) restriction enzymes (purchased from Sibenzyme, Novosibirsk, Russia) and subjected to electrophoresis on a 8% polyacrylamide gel followed by staining with ethidium bromide for UV visualization. Fragment sizes were estimated by comparison to standard DNA molecular ladders.
Statistical analysis was performed with GraphPad (http:// www.graphpad.com) and SISA (http://home.clara.net/sisa/) on-line calculators. The genotype data were analyzed using the Fisher exact test. A Bonferroni correction for multiple testing was applied. All polymorphisms examined in the present study were explored with regard to whether the genotype frequencies observed were in agreement with those predicted by the Hardy-Weinberg equilibrium.
